Stephan Targan
Appearances
- DateMay 7, 2023Background: Resolution of intestinal inflammation requires well-tuned communication between the immune compartment and the epithelium, carried out primarily via secreted mediators. The expression of these mediators is predominantly regulated by the transcription factor NF-κB…
Presenter
Speakers
- DateMay 8, 2023BACKGROUND: Mesenteric fat is increasingly believed to exert an important influence on intestinal inflammation. A hallmark of severe Crohn's disease (CD) is the accumulation of mesenteric fat around the inflamed intestine, typically in the terminal ileum…
Presenter
Speakers
Cedars-Sinai Medical Center - DateMay 9, 2023INTRODUCTION: We aimed to investigate the relationship between consumption of ultra-processed foods (UPFs) and: 1) active symptomatic disease and 2) intestinal inflammation in a cohort of adults living with inflammatory bowel disease (IBD)…
Presenter
Speakers
Cedars-Sinai Medical CenterEmory UniversityUniversity of Miami Miller School of MedicineCedars-Sinai Medical CenterCedars-Sinai Medical Center - DateMay 9, 2023BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…
Presenter
Speakers
Cedars-Sinai Medical CenterCedars-Sinai Medical CenterCedars-Sinai Medical Center - DateMay 7, 2023Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Presenter
Speakers
University of Chicago Division of the Biological SciencesWestern UniversityCedars-Sinai Medical Center - DateMay 18, 2024BACKGROUND: Previously we identified that patients with initial diagnosis of Ulcerative Colitis (UC) but subsequently had a diagnosis change to Crohn’s Disease (CD) (UC2CD) are a unique IBD subgroup with distinct serological, genetic and clinical features, including non-response to anti-TNF treatme…
Presenter
Cedars-Sinai Medical CenterSpeakers
- DateMay 18, 2024Inflammatory changes play an important role in tumorigenesis, and patients with chronic inflammatory bowel disease (IBD) are at an increased risk of developing colitis-associated cancer (CAC). However, the cellular contributions of these inflammatory changes in CAC are not well defined…
Presenter